1-[2-(1,8-dithia-dibenzo[e,h]azulene-2-ylmethoxy)-ethyl]-pyrrolidine hydrochloride | 374800-17-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫平类
• 英文名称: 1-[2-(1,8-dithia-dibenzo[e,h]azulene-2-ylmethoxy)-ethyl]-pyrrolidine hydrochloride
• 英文别名: 1-[2-(3,13-Dithiatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),2(6),4,7,9,11,14,16-octaen-4-ylmethoxy)ethyl]pyrrolidine;hydrochloride
• CAS: 374800-17-6
• 化学式: C₂₃H₂₃NOS₂*ClH
• 分子量: 430.035
• InChiKey: SXGIXBQKAAXGEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.58
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Thienodibenzoazulene compounds as tumor necrosis factor inhibitors
  申请人：Pliva farmaceutska industrija, dionicko drustvo

  公开号：US20030153750A1

  公开（公告）日：2003-08-14

  The present invention relates to the dibenzoazulene compounds represented by formula I as well as to their pharmaceutical preparations for the inhibition of tumor necrosis factor alpha (TNF-&agr;) and interleukine 1 (IL-1) in mammals at all diseases and conditions where these mediators are excessively secreted. The compounds of the present invention also demonstrate an analgetic action and can be used to relieve pain.

  本发明涉及由公式I表示的二苯并蓝化合物，以及它们的制药制剂，用于抑制哺乳动物在所有过度分泌这些介质的疾病和情况中的肿瘤坏死因子α（TNF-α）和白细胞介素1（IL-1）。本发明的化合物还表现出镇痛作用，可用于缓解疼痛。
• POLYMER
  申请人：Warwick Effect Polymers Limited

  公开号：US20130295040A1

  公开（公告）日：2013-11-07

  The application provides a method of producing a comb polymer comprising the steps of: (a) Providing: (i) a plurality of monomers which are linear, branched or star-shaped, substituted or non-substituted, and have an olefinically unsaturated moiety, the olefinically unsaturated moiety being capable of undergoing addition polymerisation; (ii) an initiator compound; the initiator compound comprising a homolytically cleavable bond. (iii) a catalyst capable of catalysing the polymerisation of the monomer; and (b) Causing the catalyst to catalyse, in combination with the initiator, the polymerisation of a plurality of the monomers to produce the comb polymer. Catalysts and polymers obtainable by the process are also provided. Preferably, the comb polymer is capable of binding proteins and may be produced from monomers which are alkoxy polyethers, such as poly(alkyleneglycol) or polytetrahydrofuran.

  该应用程序提供了一种制备梳状聚合物的方法，包括以下步骤：(a) 提供：(i) 多种单体，这些单体是线性的、分支的或星形的，取代的或非取代的，并具有烯丙基不饱和基团，烯丙基不饱和基团能够经历加成聚合；(ii) 引发剂化合物；引发剂化合物包括一个自由基裂解键；(iii) 能够催化单体聚合的催化剂；和(b) 使催化剂与引发剂结合，催化多种单体的聚合以产生梳状聚合物。该过程可获得催化剂和聚合物。优选地，梳状聚合物能够结合蛋白质，并且可以由烷氧基聚醚单体制备，例如聚(烷基二醇)或聚四氢呋喃。
• Novel antidiabetic agents
  申请人：Evans Michael David

  公开号：US20050203031A1

  公开（公告）日：2005-09-15

  Compounds which are 1-(2′-aminoacyl)-2-cyanopyrrolidine derivatives according to general formula (1) are DP-IV inhibitors for treatment of impaired glucose tolerance or type 2 diabetes; wherein A is selected from groups (2, 3 and 4); X is selected from aminoacyl groups corresponding to the natural amino acids, acyl groups R 3 CO, groups R 4 COOC(R 5 )(R 6 )OCO, methoxycarbonyl, ethoxycarbonyl and benzyloxycarbonyl; R 1 is selected from H, C 1 -C 6 alkyl residues, (CH 2 ) a NHW 1 , (CH 2 ) b COW 2 , (CH 2 ) c OW 3 , CH(Me)OW 4 , (CH 2 ) d —C 6 H 4 —W 5 and (CH 2 ) e SW 6 , where a is 2-5, b is 1-4, c is 1-2, d is 1-2, e is 1-3, W 1 is COW 6 , CO 2 W 6 or SO 2 W 6 , W 2 is OH, NH 2 , OW 6 or NHW 6 , W 3 is H or W 6 , W 4 is H or W 6 , W 5 is H, OH or OMe, and W 6 is C 1 -C 6 alkyl, optionally substituted phenyl, optionally substituted heteroaryl or benzyl and R 2 is selected from H and (CH 2 ) n —C 5 H 3 N—Y, where n is 2-4 and Y is H, F, Cl, NO 2 or CN, or R 1 and R 2 together are —(CH 2 ) p — where p is 3 or 4; R 3 is selected from H, C 1 -C 6 alkyl and phenyl; R 4 is selected from H, C 1 -C 6 alkyl, benzyl and optionally substitued phenyl; R 5 and R 6 are each independently selected from H and C 1 -C 6 alkyl or together are —(CH 2 ) m —, where m is 4-6; R 7 is selected from pyridyl and optionally substituted phenyl; R 8 is selected from H and C 1 -C 3 alkyl; and R 9 is selected from H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy and phenyl.

  根据通式(1)的 1-(2′-氨基酰基)-2-氰基吡咯烷衍生物化合物是用于治疗糖耐量受损或 2 型糖尿病的 DP-IV 抑制剂；其中 A 选自基团(2、3 和 4)；X 选自与天然氨基酸相对应的氨基酰基、酰基 R 3 CO、基团 R 4 COOC(R 5 )(R 6 )OCO、甲氧羰基、乙氧羰基和苄氧羰基； R 1 选自 H、C 1 -C 6 烷基残基、(CH 2 ) a NHW 1 ，（CH 2 ) b COW 2 ，（CH 2 ) c OW 3 , CH(Me)OW 4 , (CH 2 ) d -C 6 H 4 -W 5 和（CH 2 ) e SW 6 其中 a 为 2-5，b 为 1-4，c 为 1-2，d 为 1-2，e 为 1-3，W 1 为 COW 6 , CO 2 W 6 或二氧化硫 2 W 6 , W 2 是 OH、NH 2 OW 6 或 NHW 6 , W 3 为 H 或 W 6 , W 4 是 H 或 W 6 , W 5 是 H、OH 或 OMe，而 W 6 是 C 1 -C 6 烷基、任选取代的苯基、任选取代的杂芳基或苄基，且 R 2 选自 H 和（CH 2 ) n -C 5 H 3 N-Y，其中 n 为 2-4，Y 为 H、F、Cl、NO 2 或 CN，或 R 1 和 R 2 共同为-(CH 2 ) p - 其中 p 为 3 或 4；R 3 选自 H、C 1 -C 6 烷基和苯基 4 选自 H、C 1 -C 6 烷基、苄基和任选取代的苯基； R 5 和 R 6 各自独立地选自 H 和 C 1 -C 6 烷基，或共同为-(CH 2 ) m -，其中m为4-6；R 7 选自吡啶基和任选取代的苯基； R 8 选自 H 和 C 1 -C 3 烷基；以及 R 9 选自 H、C 1 -C 6 烷基、C 1 -C 6 烷氧基和苯基。
• METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF
  申请人：Leo Laboratories Limited

  公开号：EP3004036B1

  公开（公告）日：2017-11-22
• THIENODIBENZOAZULENE COMPOUNDS AS TUMOR NECROSIS FACTOR INHIBITORS
  申请人：GlaxoSmithKline istrazivacki centar Zagreb d.o.o.

  公开号：EP1284977B1

  公开（公告）日：2009-06-24